Zenas BioPharma to Present Orelabrutinib and MS Portfolio Data
Zenas BioPharma announced that it will present seven posters at MSToronto2026, including data on Orelabrutinib for relapsing remitting multiple sclerosis, clinical trial designs for progressive multiple sclerosis, and other data from its multiple sclerosis portfolio.